CTSS, cathepsin S, 1520

N. diseases: 131; N. variants: 10
Disease: Sjogren's Syndrome ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE Tear CTSS activity is elevated with other early disease indicators, suggesting potential as an early stage biomarker for SS. 30126300 2019
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE These findings suggest that CTSS inhibitors administered either topically or systemically can mitigate aspects of the ocular manifestations of SS. 31267034 2019
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE Tear CTSS activity is reconfirmed as a putative biomarker of SS in an independent patient cohort while combined LF and CTSS measurements may distinguish SS from DE patients. 30038391 2018
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 AlteredExpression disease BEFREE Cathepsin S (CTSS) activity is increased in tears of Sjögren's syndrome (SS) patients. 30423938 2018
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE Given the elevated activity of CTSS in SS tears, and the role intact PRG4 plays in ocular surface health and lubrication, degradation of PRG4 by CTSS is a potential mechanism for diminished ocular surface lubrication in SS. 28549901 2017
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE Mouse tear fluid was collected and tear Cathepsin S, a putative tear biomarker for Sjögren's syndrome, was measured. 28122086 2017
CUI: C1527336
Disease: Sjogren's Syndrome
Sjogren's Syndrome 		0.070 Biomarker disease BEFREE Interferon-γ treatment in vitro elicits some of the changes in cathepsin S and antigen presentation characteristic of lacrimal glands and corneas from the NOD mouse model of Sjögren's Syndrome. 28902875 2017